All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

MEMO1 is a redox protein \[[@pone.0236361.ref001]\] that acts in different signaling pathways including FGF23---FGF receptor \[[@pone.0236361.ref002]\]. Embryonic lethality results from constitutive deletion of *Memo1* \[[@pone.0236361.ref003]\], but mice conditionally lacking *Memo1* exon 2 (*Memo1* cKO) showed, after post-natal Cre-lox-mediated excision, a phenotype of premature aging and disturbed mineral homeostasis \[[@pone.0236361.ref002]\]. More precisely *Memo1* cKO mice on FVBxC57BL/6 mixed genetic background displayed growth retardation, alopecia, insulin hypersensitivity, and subcutaneous fat atrophy. Moreover, mineral homeostasis was affected, with elevated calcemia and 1,25-(OH)~2~-vitamin D~3~ serum levels, slightly higher FGF23 serum concentrations and reduced parathyroid hormone (PTH) levels compared to controls \[[@pone.0236361.ref002]\]. *Memo1* cKO mice backcrossed to C57BL/6 background showed shortened life span, a spatially heterogeneous bone phenotype consisting of osteopenia and hyperostosis, elevated calcemia and FGF23 serum concentrations, but normal serum concentrations of phosphate, 1,25-(OH)~2~-vitamin D~3~ and PTH \[[@pone.0236361.ref004]\].

Strikingly, the triad of premature aging, insulin hypersensitivity and altered mineral homeostasis identified in *Memo1* cKO mice substantially overlaps with the phenotypes of *Klotho*-deficient \[[@pone.0236361.ref005]--[@pone.0236361.ref007]\] or *Fgf23* KO mice in which altered phosphate and vitamin D metabolism are the primary triggers of aging \[[@pone.0236361.ref008]\]. Together with results obtained from several in vitro and in vivo experiments \[[@pone.0236361.ref002]\], these data suggest that MEMO1 may participate in the FGF23-KLOTHO-FGFR signaling axis.

Humans carrying loss-of-function variants of *FGF23* or *KLOTHO* suffer from familial tumoral calcinosis, a condition in which affected subjects develop ectopic calcifications. Likewise, both *Klotho*-deficient \[[@pone.0236361.ref005]\] and *Fgf23* KO mice \[[@pone.0236361.ref009]\] showed extensive soft tissue calcifications. Genetic or dietary interventions that suppressed the vitamin D axis \[[@pone.0236361.ref009]--[@pone.0236361.ref015]\] or considerably decreased the phosphate load \[[@pone.0236361.ref009], [@pone.0236361.ref016], [@pone.0236361.ref017]\] prevented premature aging, soft-tissue calcifications and other traits to a variable extent in these two mouse models.

Based on the similarities between the phenotype of the *Memo1* cKO mice and that of *Fgf23*- or *Klotho*-deficient strains, we tested the hypothesis that the *Memo1* cKO phenotype might be mediated by disturbed mineral metabolism and ectopic calcifications. We looked for soft tissue calcifications and subjected the mice to low phosphate diet or to vitamin-D deficient diet. We found that by contrast to *Fgf23*- or *Klotho*-deficient mouse models, the *Memo1* cKO mice phenotype is not influenced by the low phosphate or vitamin-D deficient diets. Further, these mice exhibit no soft tissue calcifications, and display lower serum calcification propensity. We found that this lower calcification propensity was due to higher magnesemia and showed that gene expression of *Trpm6* and *Trpm7*, two trans-epithelial magnesium channels, are upregulated in absence of *Memo1* and involved in the altered magnesium homeostasis.

Methods {#sec002}
=======

Animal studies {#sec003}
--------------

All animal experiments were conducted as approved by the veterinary service of the Canton de Vaud, Switzerland.

Inducible whole-body conditional *Memo1* KO (cKO) and inducible kidney-specific *Memo1* KO (kKO) mouse models on C57BL/6 genetic background were generated as previously described \[[@pone.0236361.ref004]\] using an allele with *Memo1* exon 2 flanked by loxP sites \[[@pone.0236361.ref002]\]. In brief, *pCX-CreER*^*TM*^*/Memo1*^*fl/fl*^ mice were treated by 3 intraperitoneal injections with 2mg tamoxifen (Sigma T5648) at 4 or 8 weeks of age, as indicated, to obtain postnatal *Memo1* deletion in *Memo1* cKO mice. *Memo1*^fl/fl^ littermates not carrying Cre underwent identical treatment to serve as controls.

For generation of *Memo1* kKO mice, B6.Cg-Tg(Pax8 rtTA2S\*M2)1Koes/J \[[@pone.0236361.ref018]\] and LC-1 transgene under a Ptet bi-1 promoter \[[@pone.0236361.ref019]\] were combined with the *Memo1*^fl/fl^ allele. The resulting males were treated for 14 days with low-dose 0.2mg/mL doxycycline hyclate (Sigma) in 2% sucrose in tap water starting at age 25 to 30 days. Male *Memo1*^fl/fl^ littermates lacking at least 1 of the other transgenes were treated with the same doxycycline dose and served as controls.

Both models were genotyped using ear punch biopsy or tail DNA using the primers: *Memo1* forward `5'-CCCTCTCATCTGGCTTGGTA-3'`, *Memo1* reverse `5'- GCTGCATATGCTCACAAAGG-3'`, *Cre* forward `5'-AGGTTCGTGCACTCATGGA-3'`, *Cre* reverse `5'-TC ACCAGTTTAGTTACCC-3'`, Pax8 rtTA forward `5'-CCATGTCTAGACTGGACAAGA-3'`, Pax8 rtTA reverse `5'-CTCCAGGCCACATATGATTAG-3'`.

Mice were maintained on standard laboratory chow containing 1% calcium, 0.65% phosphorus, 0.23% magnesium and vitamin D 1600 IU/kg, unless stated otherwise. For experimental induction of vitamin D deficiency or dietary phosphate depletion, the following protocol was used:

Two to five mice from an entire cage were randomized to receive either a control diet or a dedicated diet. Body weight of the mice was initially monitored 1--2 times weekly for phosphate depletion experiments and twice weekly for vitamin D depletion experiments. If a specific phenotype was observed, mice were followed more closely, every 1--2 days. Health status was checked at least twice weekly. End points for each mouse used in these experiments were met if at least one of the following criteria was fulfilled: 1) Loss of 10% of body weight in two consecutive measurements, 2) Body weight falling below 85% of average control littermates on the same diet, 3) Failure to thrive, move or eat, 4) Signs of distress, 5) Death. Observation of criteria 1 to 4 was followed by euthanasia.

The phosphate depletion diet contained 0.2% phosphate and was compared to a 0.8% phosphate control diet. Both diets contained, 1.2% calcium, vitamin A 4000 IU/kg, vitamin D 1000 IU/kg, vitamin E 100 mg/kg, protein 18%, crude fat 7%, lysine 14g/kg (Kliba, \#2222, Switzerland) and were introduced after weaning, 2--3 days prior to tamoxifen treatment.

Vitamin D depletion experiments were performed with a diet containing vitamin D 0 IU/kg (Altromin GmbH C1017; calcium 0.95%, phosphorus 0.8%, magnesium 0.07%, vitamin A 15000 IU/kg, vitamin E 164mg/kg, protein 18%, crude fat 5%, crude fiber 4%, lysine 1.7%) or a control diet containing 500 IU/kg vitamin D (Altromin GmbH C1000; calcium 0.93%, phosphorus 0.8%, magnesium 0.07%, vitamin D 500 IU/kg, vitamin A 14000 IU/kg, vitamin E 164mg/kg, protein 18%, crude fat 5%, crude fiber 4%, lysine 1.7%). To minimize exposure to vitamin D, diets were introduced to parental cages prior to gestation of experimental mice, after randomization.

For collection of 24 hour urine samples, metabolic cages 3600M021 (Tecniplast) were used to which mice were accustomed for 2 days prior to measurements. Mice had free access to food and water. Mice were deeply anesthetized with ketamine/xylazine and bled by orbital puncture followed by cervical dislocation.

Chemical analyses {#sec004}
-----------------

For serum and urinary analyses, specimens from several animals were combined to obtain biologically independent pools, as indicated; for *Memo1* cKO and controls, specimens from 4 individual males were pooled; for *Memo1* kKO and controls, specimens from 2 males and 2 females were combined.

Serum and urinary electrolytes were quantified by the Lausanne University Hospital central laboratory: Magnesium was measured by the xylidyl blue method, total calcium by the NM-BAPTA method, phosphate by the phosphomolybdate method, and creatinine by the modified Jaffé method. Tissue calcium content of murine thoracic aorta was measured after drying the samples at 60°C for 20h and eluted in HCl 1M over 48h using a chromogenic o-cresophthalein kit (Sigma MAK022). T50 test of calciprotein particle conversion was measured by Calciscon AG, Nidau, Switzerland, as described \[[@pone.0236361.ref020]\]. For magnesium spiking experiments, magnesium chloride was added to samples as indicated prior to performing T50 measurements.

Gene expression {#sec005}
---------------

RNA was extracted using TRI reagent (Applied Biosystems by Life Technologies) and concentration was measured by Nanodrop (Nanodrop 2000, Thermo Fisher Scientific, Waltham, MA, USA). RNA was reverse transcribed using PrimeScript RT (Takara Bio Inc, Otsu, Japan). We performed qPCR by using the SYBR Green method (Applied Biosystems by Life Technologies) on a 7500 Fast machine (Applied Biosystems). Samples were run as triplicates, and *Actb* or *Gapdh* were used as house-keeping genes for relative quantification performed by using the delta-delta CT method. For each run, melting curves were obtained in order to verify the specificity of the signal and amplified products were visualized on agarose gel. Primers were purchased from Microsynth (Switzerland), and sequences are shown in [Table 1](#pone.0236361.t001){ref-type="table"}.
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###### Primers used for qPCR.

![](pone.0236361.t001){#pone.0236361.t001g}

  Oligonucleotide      5\'-sequence-3\'
  -------------------- -------------------------------
  Slc8a1 forward       `AGAGCTCGAATTCCAGAACGATG`
  Slc8a1 reverse       `TTGGTTCCTCAAGCACAAGGGAG`
  Trpv5 forward        `TCCTTTGTCCAGGACTACATCCCT`
  Trpv5 reverse        `TCAAATGTCCCAGGGTGTTTCG`
  Calb1 forward        `AACTGACAGAGATGGCCAGGTTA`
  Calb1 reverse        `TGAACTCTTTCCCACACATTTTGAT`
  Atp2b4 forward       `CTTAATGGACCTGCGAAAGC`
  Atp2b4 reverse       `ATCTGCAGGGTTCCCAGATA`
  beta-actin forward   `GTC CAC CTT CCA GCA GAT GT`
  beta-actin reverse   `AGT CCG CCT AGA AGC ACT TGC`
  Gapdh forward        `CCA CCC AGA AGA CTG TGG AT`
  Gapdh reverse        `CAC ATT GGG GGT AGG AAC AC`
  Slc34a1 forward      `TCACAGTCTCATTCGGATTTGG`
  Slc34a1 reverse      `GGCCTCTACCCTGGACATAGAA`
  Slc34a3 forward      `CCTACCCCCTCTTCTTGGGT`
  Slc34a3 reverse      `AGAGCAACCTGAACTGCGAA`
  Cyp27b1 forward      `ATGTTTGCCTTTGCCCAGA`
  Cyp27b1 reverse      `GACGGCATATCCTCCTCAGG`
  Cyp24a1 forward      `GAAGATGTGAGGAATATGCCCTATTT`
  Cyp24a1 reverse      `CCGAGTTGTGAATGGCACACT`
  Ahsg forward         `CGACAAAGTCAAGGTGTGGTC`
  Ahsg reverse         `TCAGCTGCCTCACAGAACAGT`
  Egf forward          `GAGTTGCCCTGACTCTACCG`
  Egf reverse          `CCACCATTGAGGCAGTATCC`
  Egfr forward         `CAGAACTGGGCTTAGGGAAC`
  Egfr reverse         `GGACGATGTCCCTCCACTG`
  Trpm6 forward        `AAAGCCATGCGAGTTATCAGC`
  Trpm6 reverse        `CTTCACAATGAAAACCTGCCC`
  Trpm7 forward        `GGTTCCTCCTGTGGTGCCTT`
  Trpm7 reverse        `CCCCATGTCGTCTCTGTCGT`

Protein isolation {#sec006}
-----------------

Tissue proteins were extracted in NP-40 buffer (50 mM HEPES pH7.4; 150mM NaCl; 25mM NaF; 1mM EDTA; 5mM EGTA; 1% Nonidet P-40; 2M Na ortho-vandate, and 1mM DTT supplied with 10 μg/L leupeptin (Applichem by Axonlab), 10 μg/L aprotinin, 1mM PMSF) and lyzed by metal beads. Homogenates were spun down. For preparation of membrane protein enriched fractions, kidneys were homogenated by a Polytron (Kinematica AG, Switzerland) in sucrose buffer (250mM sucrose, 150mM NaCl, 30mM Tris pH7.5, 1mM PMSF, 10 μg/L aprotinin, 10 μg/L leupeptin, and Pepstatin) and spun down 2x10min at 1000g. Supernatants were spun down again at 100'000g for 1h; pellets were resuspended in 75uL sucrose buffer. Twenty to 50ug of protein was denaturated in Laemmli buffer containing beta-mercaptoethanol. Proteins were separated by 7%, 10% or 13% SDS-PAGE, transferred to nitrocellulose (PROTRAN, Whatman) or PVDF (BioRad) membranes and visualized using Ponceau S. After blocking in nonfat dried milk 5%-TBST, membranes were incubated with primary antibodies detecting MEMO1 1:2000 \[[@pone.0236361.ref002]\], NCX1 1:1000 \[[@pone.0236361.ref021]\], TRPV5 1:50 \[[@pone.0236361.ref022]\], anti-pan PMCA 1:500 (Sigma A7952), calbindin D28K 1:1000 (Sigma C7354), NAPI2A 1:4000 \[[@pone.0236361.ref023]\] (gift from Carsten Wagner), ACTIN 1:2000 (Sigma A2066) followed by anti-mouse or, respectively, anti-rabbit horseradish peroxidase-conjugated secondary antibodies 1:10'000 (Milian Analytica 115-035-003 and 111-035-003) and exposed using Fusion Solo (Witec). Densitometric quantification of protein signal was obtained by ImageJ (1.48v) using ACTIN as a loading control for whole-tissue lysates and Ponceau S for membrane-enriched protein fractions.

Histology {#sec007}
---------

Sectioning and staining of paraffin-embedded kidneys was performed by the Mouse Pathology Facility of the University of Lausanne. Aorta cryosections were stained in-house using standard Von Kossa staining protocols. Bone tissue and calcified rat aorta served as positive controls.

Tissue calcification imaging {#sec008}
----------------------------

For *ex vivo* analysis of whole-animal tissue calcification, a soft X-ray scout-scan mode of a SkyScan 1076 micro-computed tomography machine (Skyscan, Kontich, Belgium) was employed.

Copper reduction assay {#sec009}
----------------------

Recombinant full-length MEMO1 protein produced in *E*. *coli* was purchased from antibodies-online.com (ABIN2130536). Ascorbic acid was purchased from Fluka. An OxiSelect^™^ total antioxidant capacity assay (Cell Biolabs, STA-360) was used for copper-(II) reduction assay according to manufacturer\'s instructions using uric acid standards. MgCl~2~ was added to recombinant MEMO1 protein as indicated, and ascorbic acid was used as a positive control. All samples were run in 20μL total sample volume and in duplicates.

Data analysis {#sec010}
-------------

Data from experiments with 2 independent groups were analyzed by unpaired t-test. For analysis of 2 sources of variability in 4 experimental groups and their interaction (effects of genotype, diet, and interaction between genotype and diet), two-way ANOVA were calculated using GraphPad PRISM 5.03. A power analysis was performed using web-based software at <https://www.statstodo.com/SSizSurvival_Pgm.php> (accessed on February 10th, 2015). To detect a difference in survival rates from 0.01 to 0.5, a total of 10 animals per group was required for a type I error of 0.05 and a power of 0.8. Data from survival studies were analyzed by Log Rank (Mantel Cox) test which assumes a constant hazard ratio at all time points. Two-sided p-values \<0.05 were considered significant.

Results {#sec011}
=======

Altered renal calcium handling in *Memo1* cKO mice {#sec012}
--------------------------------------------------

We backcrossed and validated the previously described \[[@pone.0236361.ref002]\] *Memo1* cKO mouse model on a pure C57BL/6 background. We have previously described an elevated calcemia and FGF23 concentration in the serum of these mice, in addition to increased urinary calcium excretion over 24h \[[@pone.0236361.ref004]\]. Now, we characterized transport proteins involved in mineral homeostasis at a molecular level to delineate similarities or differences between the *Memo1*-deficient mice in comparison to what has been published on the phenotypically close *Klotho* or *Fgf23*---deficient models.

An assessment of the expression of the main calcium transporting molecules in the gut revealed no change between *Memo1* cKO mice and controls in the duodenum ([Fig 1A](#pone.0236361.g001){ref-type="fig"}). In the kidney, we measured transcription of genes encoding proteins involved in active calcium reabsorption of the tightly regulated distal convoluted tubule---connecting tubule (DCT-CNT). Expression of the *Trpv5* gene coding for the apical Transient Receptor Potential cation channel, subfamily V, member 5 (TRPV5) and *Calb1* coding for intracellular calbindin D28K were increased in *Memo1* cKO ([Fig 1B](#pone.0236361.g001){ref-type="fig"}). Similarly, renal transcripts of *Atp2b4* and *Slc8a1* coding for the basolaterally expressed plasma membrane Ca^2+^ ATPase 4 (PMCA4) and the sodium calcium exchanger (NCX1) were also increased upon *Memo1* deletion ([Fig 1B](#pone.0236361.g001){ref-type="fig"}).

![Increased renal calcium transport proteins in whole-body *Memo1* cKO mice.\
**A**. Gene expression of the duodenal calcium transport proteins *Trpv6*, *S100g* and *Slc8a1* revealed no difference between genotypes. **B**. Renal gene expression of *Trpv5*, *Calb1*, *Atp2b4 and Slc8a1* were increased in *Memo1* cKO compared to controls. **C-E**. Renal membrane protein-enriched fractions (C, E) and whole kidney lysates (D) were used for Western blotting of proteins corresponding to genes assessed in B. Calb-D28, calbindin D28K. **F**. Densitometric quantification of C-E. \* p \< 0.05 (t-test); n = 5 per genotype.](pone.0236361.g001){#pone.0236361.g001}

Next, we investigated these calcium transport molecules at the protein level. Membrane abundance of TRPV5 protein was increased three-fold in *Memo1* cKO ([Fig 1C](#pone.0236361.g001){ref-type="fig"}). In whole kidney lysates, the abundance of intracellular calbindin D28K protein was increased ([Fig 1D](#pone.0236361.g001){ref-type="fig"}). Finally, both NCX1 membrane protein abundance ([Fig 1E](#pone.0236361.g001){ref-type="fig"}) and PMCA membrane abundance were increased ([Fig 1C](#pone.0236361.g001){ref-type="fig"}). Densitometric quantifications of these Western blots are shown in [Fig 1F](#pone.0236361.g001){ref-type="fig"}.

Evidence for disturbed renal phosphate transport and vitamin D metabolism in *Memo1* cKO mice {#sec013}
---------------------------------------------------------------------------------------------

In order to further characterize the extent of disturbed mineral homeostasis, we assessed genetic markers of phosphate homeostasis in the kidney. We found that renal transcription of *Slc34a1* encoding sodium-dependent phosphate transporter (NAPI2A) tended to decrease in *Memo1* cKO, whereas transcription of *Slc34a3* encoding NAPI2C significantly diminished upon *Memo1* deletion ([Fig 2A](#pone.0236361.g002){ref-type="fig"}). Gene expression of *Cyp24a1* encoding the vitamin D---inactivating 24 alpha-hydroxylase was increased in *Memo1* cKO, whereas *Cyp27b1* was unchanged ([Fig 2A](#pone.0236361.g002){ref-type="fig"}). On a protein level, we found that renal NAPI2A membrane abundance was increased in *Memo1* cKO ([Fig 2B](#pone.0236361.g002){ref-type="fig"}, quantification in [Fig 2C](#pone.0236361.g002){ref-type="fig"}). Altogether, *Memo1* seems to modulate both transcriptional and protein expression level of several key players in mineral metabolism \[[@pone.0236361.ref002], [@pone.0236361.ref004]\].

![Alterations in phosphate transporters expression and vitamin D metabolism in whole-body *Memo1* cKO.\
**A**. Transcripts *Slc34a1* and *Slc34a3* coding for phosphate transporters, and genes *Cyp27b1* and *Cyp24a1* coding for vitamin D-metabolizing enzymes were assessed by kidney qPCR in controls and *Memo1* cKO. **B**. Western blot analysis showed increased membrane abundance of NAPI2a protein in *Memo1* cKO; **C**. Densitometric quantification of B. ns, not significant; \* p \< 0.05 (t-test). n = 5 per genotype.](pone.0236361.g002){#pone.0236361.g002}

No change in survival in whole-body *Memo1* cKO upon diminished systemic mineral load {#sec014}
-------------------------------------------------------------------------------------

We assessed the impact of the mineral load on disease-free survival in *Memo1* cKO mice by testing two different diets: a low phosphate diet and a vitamin D deficient diet. *Memo1* cKO and control mice were randomly assigned to low phosphate (0.02%) versus control diet containing 0.8% phosphate, or to 0 IE/kg versus 500 IE/kg of vitamin D containing diet. To ensure depletion of vitamin D in adipose tissue of mice under experimental vitamin D deficiency, the parents of experimental mice were fed a vitamin D deficient diet prior to gestation.

The 0.02% low phosphate diet decreased urinary phosphate excretion in both *Memo1* cKO and control mice ([Fig 3A](#pone.0236361.g003){ref-type="fig"}). The vitamin D- deficient diet severely reduced total serum calcium levels of both genotypes ([Fig 3B](#pone.0236361.g003){ref-type="fig"}). However, none of the two interventional diets had an impact on disease-free survival of *Memo1* cKO mice compared to *Memo1* cKO mice on the corresponding control diet ([Fig 3C and 3D](#pone.0236361.g003){ref-type="fig"}).

![Systemic mineral depletion does not affect disease-free survival of whole-body *Memo1* cKO mice.\
**A**. Dietary phosphate depletion from 0.8 to 0.02% phosphorus content decreased urinary phosphate per creatinine excretion in both *Memo1* cKO and control mice. **B**. Mice of either genotype fed vitamin D-free diet displayed lower serum calcium than those fed a diet containing 500 IU/kg vitamin-D. **C-D**. Survival analysis revealed no differences in disease-free survival of *Memo1* cKO mice fed diets varying in phosphate (C) or vitamin D content (D). IU, international units. Statistical analysis was obtained by Two-way ANOVA (A, B) and by Log Rank test (Mantel-Cox) (C, D); ns, not significant; \* p \< 0.05. n = 10 per genotype on 0.8% and 7 per genotype on 0.02% phosphate diets (A). n = 3 per condition (B). 100% equals initial n at start with the following number of animals: 14 (under 0.8% Pi diet) and 10 (under 0.02% Pi diet) animals for phosphate diets (C); 9 (for the 500 IU/kg vitamin D diet) and 8 (for the 0 IU/kg vitamin D diet) animals for the vitamin D3 diets (D).](pone.0236361.g003){#pone.0236361.g003}

Collectively, these results argue against a major influence of phosphate or vitamin D on the premature aging and death phenotype reported in *Memo1* cKO mice.

Absence of soft-tissue mineralization in *Memo1* cKO mice {#sec015}
---------------------------------------------------------

We further characterized the existence and extent of soft-tissue calcifications in *Memo1* cKO mice. We dissected the entire thoracic aorta and found that the calcium content was comparable between *Memo1* cKO mice and controls ([Fig 4A](#pone.0236361.g004){ref-type="fig"}). In addition, we investigated the abdominal aorta by histological analysis and von Kossa staining in control ([Fig 4B](#pone.0236361.g004){ref-type="fig"}) and *Memo1* cKO mice ([Fig 4C](#pone.0236361.g004){ref-type="fig"}). We did not notice any calcification in either genotype. Similarly, kidney sections stained with von Kossa revealed no calcification in control ([Fig 4D](#pone.0236361.g004){ref-type="fig"}) or *Memo1* cKO mice ([Fig 4E](#pone.0236361.g004){ref-type="fig"}). Finally, whole-body *ex vivo* X-ray scans revealed no soft tissue calcification in the whole body of *Memo1* cKO mice and controls ([Fig 4F](#pone.0236361.g004){ref-type="fig"}). Altogether, we found no evidence of tissue calcification in *Memo1* cKO mice that could explain the premature aging phenotype in contrast to what has been described for *Fgf23*- or *Klotho*-deficient mice.

![Whole-body *Memo1* cKO mice do not display ectopic calcification.\
**A**. Calcium content eluted from thoracic aortae showed no differences between *Memo1* cKO and control animals. **B-C**. Histological analysis of Von Kossa stained abdominal aortae revealed no difference between control (B) and *Memo1* cKO (C) mice. **D-E**. Renal parenchyma stained by Von Kossa showed no calcified areas in control (D) or *Memo1* cKO (E). **F**. Whole-body X-ray scans of control and *Memo1* cKO mice showed no extensive tissue calcification in either genotype. ns, not significant (t-test). Scale bars: 200 μm (B-C), 100 μm (D-E). n = 16 controls and 21 *Memo1* cKO mice (A); representative images of 2 per genotype (B-C and F) and 3 per genotype (D-E).](pone.0236361.g004){#pone.0236361.g004}

Decreased serum calcification propensity and higher plasma magnesium concentration in *Memo1* cKO mice {#sec016}
------------------------------------------------------------------------------------------------------

The absence of soft tissue calcifications in *Memo1* cKO mice led us to investigate the overall calcification propensity in the mouse serum by nephelometry that measures conversion from spontaneously formed primary to secondary calciprotein particles (CPPs) \[[@pone.0236361.ref020]\]. Maximal light scattering in relative nephelometry units (RNU) was decreased in the sera of all *Memo1* cKO mice compared to controls ([Fig 5A](#pone.0236361.g005){ref-type="fig"}). In addition, T50 time of conversion from primary to secondary CPPs was prolonged in *Memo1* cKO mice, indicating a diminished tendency to form secondary CPPs ([Fig 5A](#pone.0236361.g005){ref-type="fig"}). Consequently, we assessed the presence of putative calcification inhibitors in *Memo1* cKO mice sera. We measured transcription of *Ahsg* encoding Fetuin-A by qPCR in the liver, but this was unchanged in *Memo1* cKO compared to controls ([Fig 5B](#pone.0236361.g005){ref-type="fig"}). Magnesium is another strong inhibitor of calcification. We pooled serum samples of 24 individual mice per genotype into 6 independent biological samples per genotype and found substantially increased serum magnesium concentrations in *Memo1* cKO compared to controls ([Fig 5C](#pone.0236361.g005){ref-type="fig"}) (1.07 ± 0.04 mmol/L vs 0.87 ± 0.04 mmol/L, p\<0.001). Of note, urinary excretion rates of magnesium over 24h were comparable between the genotypes ([Fig 5D](#pone.0236361.g005){ref-type="fig"}).

![Altered magnesium homeostasis protects whole-body *Memo1* cKO mice from ectopic mineralization.\
**A**. T50 test. Nephelometric light scattering of spontaneously forming primary and secondary calciprotein particles was measured (left panel). Sera from *Memo1* cKO displayed lower relative nephelometry units (RNU) upon formation of secondary calciprotein particles and longer conversion from primary to secondary particles was increased (right panel), indicating lower propensity to calcify. **B**. Hepatic expression of gene *Ahsg* encoding fetuin-A was comparable between genotypes. **C**. *Memo1* cKO showed higher serum magnesium concentrations than control animals. **D**. Urinary magnesium excretion per 24h was comparable in both genotypes. **E**. In the ileum, *Memo1* cKO mice revealed higher transcription of *Trpm6* than controls, whereas *Trpm7* was unchanged. **F**. In kidney qPCR both *Trpm6* and *Trpm7*, and transcripts of *Egf* were increased in *Memo1* cKO compared to controls. \* p \< 0.05 (t-test); ns, not significant. n = 5 per genotype (A-B, E-F); sera of 24 male and female mice aged 12 weeks pooled to 6 independent samples per genotype (C); 11 controls and 13 *Memo1* cKO (D).](pone.0236361.g005){#pone.0236361.g005}

To delineate the mechanisms of the observed difference in serum magnesium levels, we quantified transcripts levels of genes encoding magnesium channels in the intestine and in the kidney. Transcripts of *Trpm6* encoding Transient Receptor Potential cation channel, subfamily M, member 6 (TRPM6) but not *Trpm7* were increased in the ileum of *Memo1* cKO mice compared to controls ([Fig 5E](#pone.0236361.g005){ref-type="fig"}), suggesting a state of increased intestinal magnesium absorption through TRPM6 in the gut. In the kidney of *Memo1* cKO mice, both *Trpm6* and *Trpm7* expression were increased ([Fig 5F](#pone.0236361.g005){ref-type="fig"}). As renal magnesium handling is influenced by epidermal growth factor receptor (EGFR) signaling \[[@pone.0236361.ref024]\], we investigated transcriptional levels of the genes *Egf* and *Egfr*. Renal *Egf* was increased in *Memo1* cKO, but *Egfr* was unchanged ([Fig 5F](#pone.0236361.g005){ref-type="fig"}).

Next, we investigated whether the higher plasma magnesium level could explain by itself the decreased serum calcification propensity of *Memo1* cKO mice. We pooled serum samples of 24 individual mice per genotype into 6 independent biological samples and measured the mean difference of magnesium concentration between the two genotypes, which amounted to 0.2 mmol/L. We then spiked serum samples of *Memo1* cKO mice and controls with the same amount of magnesium and measured calcification propensity. This intervention shifted the T50 calcification propensity of spiked control mouse serum to a level comparable to native unspiked serum of *Memo1* cKO ([Fig 6](#pone.0236361.g006){ref-type="fig"}). In an experimental control of independently pooled serum from 6 wildtype mice, spiking with 0.2 mmol/L magnesium chloride increased the T50 test from 206 min to 231 min. Taken together, these data indicate that mice are protected from ectopic calcifications by higher serum magnesium resulting from increased expression of magnesium transporting molecules in the kidneys and the gut.

![Difference in serum magnesium levels accounts for altered serum calcification propensity in *Memo1* cKO mice.\
Serum samples were analyzed either untreated or after spiking with 0.2mmol/L magnesium chloride, the difference observed in serum magnesium levels between the two genotypes. The resulting T50 test of calciprotein conversion approximated a similar range in spiked sera of control mice when comparing with unspiked *Memo1* cKO. \*, p \< 0.05 (t-test); ns, not significant. Sera of 24 mice pooled to 6 independent samples per genotype.](pone.0236361.g006){#pone.0236361.g006}

Loss of *Memo1* in the kidney elevates magnesemia but is partially compensated by decreased intestinal magnesium channel expression {#sec017}
-----------------------------------------------------------------------------------------------------------------------------------

Finally, given the essential role of the kidney in magnesium homeostasis, we hypothesized that loss of *Memo1* in the kidney alone could increase renal magnesium reabsorption leading to higher serum magnesium. We have previously established and characterized a model of renal tubule-specific inducible *Memo1* exon 2 deletion using the doxycycline-inducible Pax8-rtTA and LC1 Cre transgenes, as reported elsewhere \[[@pone.0236361.ref025]\]. Mice were treated with low-dose doxycycline and *Memo1* kKO displayed kidney-specific loss of MEMO1 protein ([Fig 7A](#pone.0236361.g007){ref-type="fig"}). Measurement of serum magnesium concentrations in this model, revealed a significantly increased mean value in the *Memo1* kKO mice (1.03 ± 0.04 mmol/L vs 0.97 ± 0.02 mmol/L, p = 0.049) ([Fig 7B](#pone.0236361.g007){ref-type="fig"}), but of lower magnitude compared to *Memo1* cKO mice. Fractional excretion of magnesium in the urine was comparable between the two genotypes ([Fig 7C](#pone.0236361.g007){ref-type="fig"}).

![Kidney-specific *Memo1* kKO mice displayed elevated magnesemia and renal magnesium channel transcription.\
**A**. Renal-specific loss of MEMO1 in *Memo1* kKO was verified using Western blots of whole organ lysates. **B**. Magnesium concentration of sera pooled from 4 independent animals per data point (n = 4x4) was elevated in *Memo1* kKO compared to controls. **C**. Fractional excretion of magnesium was comparable between pools of 4x4 independent murine spot urines per genotype. **D**. In serum pools of (4x4) *Memo1* kKO and controls, T50 test of calciprotein conversion was comparable, and spiking with 0.06 mmol/L magnesium chloride caused no significant change in T50 test of serum calcification propensity. **E**. In ileum, gene expression of *Trpm6* tended to decrease and *Trpm7* significantly decreased in *Memo1* kKO compared to controls. **F**. In the kidney *Trpm6* tended to increase and *Trpm7* significantly increased in *Memo1* kKO, whereas *Egf* and *Egfr* transcription were unchanged. p \< 0.05 (t-test); ns, not significant. n = 1 per genotype (A) but representative of several experiments; sera or spot urines of 16 male mice age 8 weeks pooled to 4 independent samples per genotype (B-D); 5 per genotype (E-F).](pone.0236361.g007){#pone.0236361.g007}

Probably owing to the small difference in serum magnesium, the *Memo1* kKO mice showed a serum calcification propensity that was comparable to that of control mice ([Fig 7D](#pone.0236361.g007){ref-type="fig"}). In this kidney-specific knockout model *Memo1* kKO, we found that ileal expression of *Trpm7* was decreased and that *Trpm6* showed a trend for a decrease in *Memo1* kKO, suggesting a lower magnesium absorption from the intestine ([Fig 7E](#pone.0236361.g007){ref-type="fig"}). However, the renal tissue directly affected by the Cre/lox-mediated *Memo1* exon2 excision showed increased *Trpm7* and *Trpm6* expression ([Fig 7F](#pone.0236361.g007){ref-type="fig"}). Both renal *Egf* and *Egfr* gene expression were unaffected in this model ([Fig 7F](#pone.0236361.g007){ref-type="fig"}). We spiked the small but significant difference in magnesemia between *Memo1* kKO and controls, amounting 0.06mmol/L, ([Fig 7D](#pone.0236361.g007){ref-type="fig"}) to serum samples, and we measured the T50 test of serum calcification propensity. No difference was noted between the spiked and unspiked groups ([Fig 7D](#pone.0236361.g007){ref-type="fig"}). However, in an experimental control of pooled serum from 6 wildtype mice, adding 0.06 mmol/L magnesium chloride slightly increased the T50 test from 206 min to 214 min.

No evidence for a direct magnesium-dependent oxidative function of recombinant MEMO1 protein {#sec018}
--------------------------------------------------------------------------------------------

Since MEMO1 display copper-reducing activity without any known physiological substrate \[[@pone.0236361.ref001]\], we tested whether MEMO1\'s redox function might be magnesium-dependent. We measured copper-reducing activity of different magnesium chloride concentrations either alone or in presence of 2μg of recombinant MEMO1. While magnesium chloride alone had a slight dose-dependent copper-reducing effect up to 10mM, it did not influence the copper-reducing activity in presence of MEMO1 ([Fig 8A](#pone.0236361.g008){ref-type="fig"}). By contrast, magnesium chloride increased the copper-reducing activity of the known antioxidant ascorbic acid that we used as a positive control ([Fig 8B](#pone.0236361.g008){ref-type="fig"}).

![No evidence for a direct magnesium-dependent oxidative function of recombinant MEMO1 protein.\
**A**. Addition of indicated concentrations of magnesium chloride did not alter copper-reducing function of recombinant MEMO1 protein, but magnesium chloride alone showed a dose-dependent copper-reducing effect up to 10mM. **B**. Magnesium chloride increased the copper-reducing activity of ascorbic acid. All samples were analyzed in duplicates.](pone.0236361.g008){#pone.0236361.g008}

Discussion {#sec019}
==========

*Memo1* cKO mice share some characteristics with *Klotho* and *Fgf23*-deficient strains including higher levels of plasma calcium, phosphate and vitamin D which are thought to be causes of increased tissue calcification and premature aging. We assessed whether a decrease in systemic mineral load could prevent premature aging and death in *Memo1* cKO mice. However, neither a low phosphate diet nor a vitamin D deficient diet rescued the survival of *Memo1* cKO mice, which is in contrast to what has been observed in *Klotho* and *Fgf23*-deficient mice.

This illustrates several key differences between the phenotype of *Memo1-* and *Fgf23-* or *klotho*-deficient mice. *Memo1* cKO mice display (i) a distinct bone phenotype due to alkaline phosphatase dysfunction, (ii) absence of soft tissue calcifications and (iii) no rescue by low phosphate or vitamin-D deficient diets. This suggests that *Memo1* cKO mice are resistant to calcification and thus a different mechanism causes their premature aging compared to *Fgf23-* or *klotho*-deficient mice. We indeed found that *Memo1* cKO mice are less prone to overall calcification (tissues and serum calcification propensity). We identified higher serum magnesium concentration in *Memo1* cKO mice as one of the main causes, in the absence of any change in serum albumin concentration or in liver Fetuin A-coding gene expression (*Ahsg)*, two main protectors against calcification in the serum.

These results led us to investigate magnesium homeostasis in the *Memo1* cKO and the kidney-specific *Memo1* kKO mouse models. While mice of both models showed higher serum magnesium concentrations, we observed model-specific differences in the tissue-specific regulation of the magnesium transport proteins. We found an increase in the expression of the magnesium channels *Trpm6* and *Trpm7* in the ileum and the kidneys of the whole body MEMO1-deficient mice *Memo1* cKO. Interestingly, kidney-specific MEMO1-deficient *Memo1* kKO mice showed increased *Trpm7* transcripts only in the kidney and a decreased expression in the intestine, suggestive of an intestinal compensation mechanism that keeps plasma magnesium concentration close to the normal range. This may explain the only small elevation of magnesium levels and the similar calcification propensity observed in sera of *Memo1* kKO animals. Overall, we propose that MEMO1 has a role in the regulation of *Trpm6* and *Trpm7* gene expression, as has been previously described for other transport proteins involved in phosphate and calcium homeostasis \[[@pone.0236361.ref002], [@pone.0236361.ref025]\]. Some data are suggestive that phospholipase C has a role in this regulation \[[@pone.0236361.ref026]--[@pone.0236361.ref028]\], but the precise molecular mechanisms underlying MEMO1regulation of *Trpm7* expression remain unknown.

As MEMO1 participates in multiple cellular functions, some of them only partially understood, the current data reveal a new physiological axis for MEMO1. Although we can only speculate why MEMO1-deficient tissues increase magnesium channels, we propose a combination of different mechanisms that might contribute to explaining our results:

1.  MEMO1 might crosslink magnesium and phosphate homeostasis due to its function downstream of both EGFR and FGFR signaling pathways. We have previously shown that MEMO1-deficient cells are resistant to treatment with EGF \[[@pone.0236361.ref004]\] and FGF23 \[[@pone.0236361.ref002]\]. In the same line, antibody-mediated EGFR inhibition was recently shown to reduce renal phosphate excretion and concomitantly to decrease magnesemia in mice \[[@pone.0236361.ref029]\]. MEMO1 may thus be involved in the crosstalk between the two pathways.

2.  Regarding phosphate regulation, we have previously shown that *Memo1* cKO mice have decreased renal phosphate transporter expression \[[@pone.0236361.ref002]\], but preserved phosphatemia. Normal serum phosphate concentration might be explained by the opposite role of MEMO1 on EGFR and FGFR signaling. More specifically, loss of MEMO1 impairs cellular response to FGF23 and decreased NaPi2a and NaPi2c expression \[[@pone.0236361.ref002]\], thus decreasing renal phosphate excretion, while higher renal *Egf* expression favors phosphate excretion \[[@pone.0236361.ref030], [@pone.0236361.ref031]\]. A decreased renal FGF23 response but increased paracrine EGF activity in the kidney may result, which could explain the normal serum phosphate concentrations in *Memo1* cKO \[[@pone.0236361.ref002], [@pone.0236361.ref004]\].

3.  Intriguingly, *Trpm7* which is transcriptionally increased in the two *Memo1* KO mouse models presented here, is needed for EGF-induced cancer cell migration \[[@pone.0236361.ref032]\], a function apparently opposite to *Memo1*'s role in cancer cell motility, where MEMO1 expression is upregulated \[[@pone.0236361.ref027]\]. The increased expression of *Trpm7* induced by EGF or by the absence of *Memo1* with opposite role on cancer cell migration will require more in-depth studies.

4.  Oxidative dysregulation found in *Memo1*-deficient cells \[[@pone.0236361.ref001]\] may directly affect the TRPM channel-kinase activity: indeed TRPM6 is suppressed by hydrogen peroxide, and TRPM7 acts as a sensor for mitochondrial oxidative stress \[[@pone.0236361.ref033]--[@pone.0236361.ref036]\]. In addition, vitamin C synthesis \[[@pone.0236361.ref037]\] and its transport into tissues via sodium-dependent vitamin C transporter 2 \[[@pone.0236361.ref038]\] is facilitated by increased magnesium concentrations. This would likely be beneficial for an organism under oxidative stress \[[@pone.0236361.ref039]\]. Evidence for such physiological compensation mechanisms is however lacking and should be directly assessed in more mechanistic studies.

5.  Loss of *Memo1* affects alkaline phosphatase activity in bone and serum \[[@pone.0236361.ref004]\] and alkaline phosphatase activity depends on magnesium. Thus, an increased magnesium concentration would help rescue alkaline phosphatase activity \[[@pone.0236361.ref040]\] and overall benefit bones in *Memo1* cKO mice.

It is also important to discuss the limitations of this study. First, the effect of magnesium on serum T50 values might be seen as small compared to what has been previously described \[[@pone.0236361.ref020]\]. However, the current data stem from C57BL/6 mouse sera, in contrast to previous studies \[[@pone.0236361.ref020]\] that used mice maintained on the DBA genetic background. Mice with DBA background show lower magnesium concentrations and are more prone to soft-tissue calcifications \[[@pone.0236361.ref041]\]. Second, *Memo1* cKO mice showed an increase in renal *Egf* mRNA expression, but *Memo1* kKO did not. The comparability of the two models is however limited by the chronic kidney disease (CKD) that develops in *Memo1* cKO \[[@pone.0236361.ref004]\] but not in *Memo1* kKO mice which have normal serum creatinine levels \[[@pone.0236361.ref002]\]. Indeed, CKD may itself increase EGF levels \[[@pone.0236361.ref042]\].

In conclusion, loss of the redox protein MEMO1 alters magnesium homeostasis and, in the case of whole-body MEMO1 depletion, decreases serum calcification propensity. Magnesium protects from vascular calcification in rodents \[[@pone.0236361.ref043]\] and from progression to end-stage renal disease in hyperphosphatemic patients \[[@pone.0236361.ref044], [@pone.0236361.ref045]\]. In addition, targeting oxidative stress is considered a promising strategy for both acute kidney injury \[[@pone.0236361.ref046]--[@pone.0236361.ref048]\] and chronic kidney disease \[[@pone.0236361.ref049]\]. The current data highlight another potential relevance of such strategies in reducing soft tissue calcification, a critical contributor to mortality in kidney disease.
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Dear Dr. Bonny,

I hope this note finds you well. We're all in a bit of a fog coping with the c19 pandemic. At some level, it seems odd to be concerned with esoteric scientific problems with so much more at stake. That said, I now received reviews on your submitted work from two internationally respected experts. Both found your work of substantial potential interest but raised a number of salient questions and concerns that will have to be favorably addressed before a final decision can be reached.

Reviewer \#1 raises the obvious and sensible question regarding the paradoxical increase of Npt2a with elevated Fgf23 levels, when reduced transporter expression would be expected. Moreover, if Npt2a is elevated, what counterregulatory mechanism keeps serum Pi normal?

Reviewer \#2 expressed greater reservations and questions whether MEMO1 deficiency causes such profound pathology that the phenotype arises secondarily. The reviewer also notes the apparent contradictory findings with Fgf23 and Npt2a, along with other significant concerns. Some suggestions for addressing these perceived deficiencies are included by both reviewers.

The journal looks forward to your response and an amended manuscript.

We would appreciate receiving your revised manuscript by May 21 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

With kind regards,

Peter A. Friedman, Ph.D. (a former Institut fellow)

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Competing Interests section:

\"is an inventor of the T50-Test and stock-holder and employee of Calciscon AG, which commercialized the T50-Test (calcification propensity test). MB is an employee of Calciscon AG. The other authors declare that no conflict of interest exists.\"

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.
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4\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5\. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript by Moor et al describes a potential mechanism for the reduction of calcifications in Memo-1 deficient mice. The authors' work suggests this could be due to a role of Memo-1 in magnesium handling. Overall, the work adequately supports the hypothesis, however several clarifications should be made:

1\) It is not clear why in the cKO mouse that if FGF23 is elevated, why is NPT2a increased, when a principle action of FGF23 is to down-regulate this protein? Further, why are there conflicting data with the 24-OHase mRNA levels? It appears as if this gene is properly regulated by the elevated FGF23, as it shows increased expression.

2\) Would suggest that the mice be re-assessed with the Quidel Rodent specific FGF23 intact ELISA, not the Kainos human FGF23 ELISA that was used previously.

3\) If NPT2a is elevated, what is the counter regulatory mechanism to keep the serum Pi normal in the cKO mice since 1,25D and PTH are normal?

4\) It is clear that FGF23 and KL are genes involved in phosphate handling, and are not true aging-related genes as in progeria. References to aging-like phenotypes in the cKO mouse model should be minimized in the Introduction and a sentence should be added that these phenotypes can be explained by altered phosphate and vitamin D handling.

5\) If possible, in vitro experiments would strengthen the idea that Memo-1 directly controls Trpm6-7 expression.

Reviewer \#2: Mediator of cell ErbB2-driven MOtility1 (MEMO1) is a ubiquitously expressed protein with vital functions. Structurally, MEMO1 is related to iron- and zinc-binding enzymes, and exerting a Cu-II dependent oxidase activity affecting the cellular redox status and controlling the activity of a wide range of redox-regulated cellular proteins. MEMO1 affects cellular motility presumably by direct interaction with cellular motility proteins, and in addition through scaffolding of signalosomes. Thus MEMO1 exhibits profound protein moonlighting, which renders in vivo studies near impossible because or complex interaction and interdependencies of the claimed functions. Whole body MEMO1 knockout is embryo lethal, while conditional knockout cKO produces a complex phenotype of growth retardation and drastically reduced life span (mean survival about 2 months). These findings suggest that MEMO1 deficiency renders the animals profoundly sick and that it will be very difficult to decide if aspects of the phenotype are the cause or a consequence of the progressively poorer health status of the animals, again begging the question, which of the many claimed functions of MEMO1 is chief in this scenario. Studies suggested that a major function of MEMO1 is enhancing FGF signaling by stabilizing the FGFR signalosome. This broad function downstream of receptor tyrosine kinases was narrowed down when it was realized that the MEMO1 cKO phenotype was similar to the phenotype of FGF23 and klotho deficient mice. This finding put MEMO1 into FGF23-klotho phosphaturic signaling, however with one major shortcoming, namely that the overt hyperphosphatemia of FGF23 and klotho knockout mice that is meant to be instrumental for a large part of the detrimental knockout phenotypes is completely absent in MEMO1 cKO. One driving feature of FGF23 and klotho knockout morbidity is pathological calcification, which can be (partially) rescued by low phosphate diet or by reducing Vit D activity in the mice. Against this background the authors study calcification in MEMO1 cKO mice and unlike in FGF23 mice, find none. Dietary phosphate or vitamin-D restriction do not change the survival of the MEMO1 cKO mice. The authors report however, slight differences in serum calcification propensity, that they attribute to serum Mg.

The amount and quality of work presented in the manuscript make it well worth reporting even if it were purely descriptive. In the current mechanistic presentation I have great difficulties following the authors' reasoning, especially that a slight change in serum magnesium will affect the health of the animals so profoundly.

Major points

1\) It would help a lot if the authors would lay out their working hypothesis more clearly given the many purported functions of MEMO1, especially since some of the crucial disturbances in mineral handling observed in FGF23 and klotho mice are completely absent in MEMO1 cKO mice, or minor at best.

Minor points

1\) Hyperphosphatemia and calcification are absent in the mice, why go on and study calcification propensity? Please explain.

2\) Experimental diets; 0.65% phosphorous in the control diet is still pretty high, 0.8% definitely is. For comparison see a recent study by Babler et al. 2020 PLoS ONE (<https://doi.org/10.1371/journal.pone.0228938>)

3\) The differences in control serum magnesium in Fig 5C and Fig 7B are almost as large like the differences between control and kKO. Please discuss.

4\) Fig 4F x-rays are pretty bad quality. Since the authors used a Skyscan micro-CT, can they provide higher resolution CT scans? Perhaps these would show microcalcifications.

5\) Fig 7 and the function of Mg transporters in various tissues, please discuss against a recent publication on this topic (Chubanov et al. 2016, [doi.org/10.7554/eLife.20914](http://doi.org/10.7554/eLife.20914))

6\) Fig 9 does not add any information to the text, delete.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Willi Jahnen-Dechent

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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REPLY to the EDITOR and the REVIEWERS: available in a separate document in FULL. Here is only a short version of it:

Dear Dr. Bonny,

I hope this note finds you well. We're all in a bit of a fog coping with the c19 pandemic. At some level, it seems odd to be concerned with esoteric scientific problems with so much more at stake. That said, I now received reviews on your submitted work from two internationally respected experts. Both found your work of substantial potential interest but raised a number of salient questions and concerns that will have to be favorably addressed before a final decision can be reached.

Reviewer \#1 raises the obvious and sensible question regarding the paradoxical increase of Npt2a with elevated Fgf23 levels, when reduced transporter expression would be expected. Moreover, if Npt2a is elevated, what counterregulatory mechanism keeps serum Pi normal?

Reviewer \#2 expressed greater reservations and questions whether MEMO1 deficiency causes such profound pathology that the phenotype arises secondarily. The reviewer also notes the apparent contradictory findings with Fgf23 and Npt2a, along with other significant concerns. Some suggestions for addressing these perceived deficiencies are included by both reviewers.

Dear Dr Friedman,

Many thanks for your kind words. I also hope that you are doing fine. Apart of treating covid19 patients, we also found the time to address the different points raised by the two reviewers and thank them for their interesting and constructive comments. In accordance with the pointed issues, we changed the text when needed.

We hope that the manuscript will be now acceptable for the readership of PLoSOne.

Best regards

Olivier Bonny, in the name of the co-authors

Response to the reviewers:

Reviewer \#1: The manuscript by Moor et al describes a potential mechanism for the reduction of calcifications in Memo-1 deficient mice. The authors' work suggests this could be due to a role of Memo-1 in magnesium handling. Overall, the work adequately supports the hypothesis, however several clarifications should be made:

1\) It is not clear why in the cKO mouse that if FGF23 is elevated, why is NPT2a increased, when a principle action of FGF23 is to down-regulate this protein? Further, why are there conflicting data with the 24-OHase mRNA levels? It appears as if this gene is properly regulated by the elevated FGF23, as it shows increased expression.

We agree and are also puzzled by the differential regulation of NaPi2a and 1,25-D in the Memo1 KO mouse model. We have no definitive mechanistic explanations for this observation based on in vivo data. We can only speculate that FGF23-driven signaling is not regulating NPT2a as expected (as previously shown by Haenzi B et al., FASEB J, 2014), and hence NPT2a mRNA is not repressed in Memo1-cKO mice kidney. One possible explanation suggested by Haenzi et al regards the processing of NPT2a. Haenzi et al have found that the quantity of the clived 40KDa fragment of NPT2a was reduced in Memo1 KO mice renal BBMVs. However, this was confirmed neither in the present work nor in the kidney-specific Memo1-KO mouse model (Moor et al, Front in Physiol). Moreover, the significance of NPT2a cleavage is unknown to the best of our knowledge.

It should also be pointed out here that NPT2c gene expression, by contrast, is consistently decreased in all Memo1 KO mouse models and thus responds the expected way to FGF23.

The 24-OHase mRNA increase in Memo1 KO mice is associated with increased FGF23 in Memo whole-body KO but was not found in kidney-specific KO animals (Moor et al., Front Physiol 2018), not suggesting a causal relationship of this finding in the present study.

Overall, it seems that Memo1 is regulating transcriptionally and/or post-translationally some specific transporters involved in mineral metabolism, including NPT2a, but without affecting phosphate homeostasis. As a reminder, data on calcium transporters indicate that the absence of Memo1 changes the transcriptional and post-translational expression pattern of NCX1, TRPV5 and calbindinD28k.

Further in vitro studies need to be performed in order to explore the apparent contradiction on the regulation of phosphate co-transporters and vitamin D in these mice but are beyond the scope and message of this paper. A dedicated manuscript addressing FGF23 regulation in Memo1 cKO mice is in preparation.

2\) Would suggest that the mice be re-assessed with the Quidel Rodent specific FGF23 intact ELISA, not the Kainos human FGF23 ELISA that was used previously.

We thank this reviewer for this suggestion and will consider a mouse kit for future studies. This was not available to our knowledge when the current study was conducted. In that period the human Kainos kit was standard in the field, and the kit is validated for use in mouse, rat and monkey according to the manufacturer.

3\) If NPT2a is elevated, what is the counter regulatory mechanism to keep the serum Pi normal in the cKO mice since 1,25D and PTH are normal?

This is an intriguing point that remains unsolved so far. We have not performed detailed phosphate balance and have no data on intestinal absorption and proximal tubule phosphate absorption. Additionally, Memo1-KO mice have impaired bone mineralization that may contribute to keep phosphatemia in the normal range (Moor et al, JBMR Plus 2018). As discussed previously, the discrepancy in the expression of NaPi2a (increased in BBMV) and NaPi2c (mRNA decreased) may also partially compensate, even if both phosphate transporters have distinct transport characteristics and that NPT2C KO mice have no obvious phosphate phenotype.

4\) It is clear that FGF23 and KL are genes involved in phosphate handling, and are not true aging-related genes as in progeria. References to aging-like phenotypes in the cKO mouse model should be minimized in the Introduction and a sentence should be added that these phenotypes can be explained by altered phosphate and vitamin D handling.

As developed in the paper by Haenzi et al (FASEB J, 2014), Memo1 cKO mice do display several traits evoking premature aging not directly related to possible alteration of the mineral metabolism: alopecia, grey hairs, subcutaneous fat atrophy, gonad atrophy, renal insufficiency and insulin resistance.

Moreover, Kl KO mice have a more complex phenotype than just alteration of the mineral metabolism that includes also anti-oxidant properties (Brobey RK et al, PLoS One. 2015).

In order to follow on the comment of the reviewer, we modified the introduction and abstract as requested by adding a sentence stating that Kl and Fgf23 KO mice have disturbances of the mineral metabolism as major trigger for the observed phenotype.

5\) If possible, in vitro experiments would strengthen the idea that Memo-1 directly controls Trpm6-7 expression.

Memo1 overexpression was lethal in the laboratory of co-author Nancy Hynes, hence we decided not to pursue co-expression studies that would address this point. In addition, there is no association between MEMO1 and TRPM6 expression in RNAseq of 1457 cell lines in Cancer Cell Line Encyclopedia, see illustration below.

Reviewer \#2: Mediator of cell ErbB2-driven MOtility1 (MEMO1) is a ubiquitously expressed protein with vital functions. Structurally, MEMO1 is related to iron- and zinc-binding enzymes, and exerting a Cu-II dependent oxidase activity affecting the cellular redox status and controlling the activity of a wide range of redox-regulated cellular proteins. MEMO1 affects cellular motility presumably by direct interaction with cellular motility proteins, and in addition through scaffolding of signalosomes. Thus MEMO1 exhibits profound protein moonlighting, which renders in vivo studies near impossible because of complex interaction and interdependencies of the claimed functions. Whole body MEMO1 knockout is embryo lethal, while conditional knockout cKO produces a complex phenotype of growth retardation and drastically reduced life span (mean survival about 2 months). These findings suggest that MEMO1 deficiency renders the animals profoundly sick and that it will be very difficult to decide if aspects of the phenotype are the cause or a consequence of the progressively poorer health status of the animals, again begging the question, which of the many claimed functions of MEMO1 is chief in this scenario. Studies suggested that a major function of MEMO1 is enhancing FGF signaling by stabilizing the FGFR signalosome. This broad function downstream of receptor tyrosine kinases was narrowed down when it was realized that the MEMO1 cKO phenotype was similar to the phenotype of FGF23 and klotho deficient mice. This finding put MEMO1 into FGF23-klotho phosphaturic signaling, however with one major shortcoming, namely that the overt hyperphosphatemia of FGF23 and klotho knockout mice that is meant to be instrumental for a large part of the detrimental knockout phenotypes is completely absent in MEMO1 cKO. One driving feature of FGF23 and klotho knockout morbidity is pathological calcification, which can be (partially) rescued by low phosphate diet or by reducing Vit D activity in the mice. Against this background the authors study calcification in MEMO1 cKO mice and unlike in FGF23 mice, find none. Dietary phosphate or vitamin-D restriction do not change the survival of the MEMO1 cKO mice. The authors report however, slight differences in serum calcification propensity, that they attribute to serum Mg.

The amount and quality of work presented in the manuscript make it well worth reporting even if it were purely descriptive. In the current mechanistic presentation I have great difficulties following the authors' reasoning, especially that a slight change in serum magnesium will affect the health of the animals so profoundly.

We thanks this reviewer for his perfect summary of the knowledge about Memo1's role in physiology. We agree that the phenotype of cKO mice is complex and might be influenced by the rapid decline of mice health and many confounding factors. This is precisely the reason why we performed the experiments early after KO induction in order to avoid most of the confounding factors.

We must state here as well that when we started this project, we had data from Haenzi et al, FASEB J showing that MEMO1 cKO had high 1,25-D and hypercalcemia. At that time, ectopic tissue calcifications were not looked at. Even if phosphatemia was normal, higher plasma calcium and calcitriol level were highly suggestive for possible ectopic calcification as being central to premature aging. We thus performed the low phosphate and low D diet experiments. We noticed that Memo1 cKO mice that have been backcrossed on a pure C57BL/6 genetic background displayed normal levels of vitamin D, similar to Klotho mice that were backcrossed to C57BL/6 where variants in Cyp24a1 gene were responsible for this discrepancy between mouse strains (Singh A, Aging Cell 2019). As serum calcium and phosphate homeostasis are tightly regulated, we hypothesized that subtle changes in calcium and phosphate fluxes might still take place and explain the phenotype and look for surrogate markers of calcification propensity. We also noted that all distal calcium transporters are upregulated in Memo1 cKO mice, but the slightly elevated calcemia is not exceeding the normal range, probably due to compensation mechanisms taking place in the bone/gut/other tubular segments.

Regarding the effect of magnesium on calcification propensity, we remind here that Pasch et al have clearly shown that even small addition of magnesium (spike with 0.25mmol) did modify the T50 substantially (Pasch et al, JASN 2012).

Even if Memo1 cKO mice have no hyperphosphatemia or major alterations of mineral metabolism, we are still impressed by the lower T50 present in these mice and the higher serum magnesium concentration. This is the main finding of this study that started from another perspective.

Major points

1\) It would help a lot if the authors would lay out their working hypothesis more clearly given the many purported functions of MEMO1, especially since some of the crucial disturbances in mineral handling observed in FGF23 and klotho mice are completely absent in MEMO1 cKO mice, or minor at best.

We now modified the introduction, and more specifically the paragraph presenting the hypothesis at the end of the introduction.

Minor points

1\) Hyperphosphatemia and calcification are absent in the mice, why go on and study calcification propensity? Please explain.

Calcification propensity assess more than hyperphosphatemia and tissue calcification. It reflects the long term risk of calcification. And long term is not appreciable in Memo1 KO mice, as they live only about 2 months at best. This is the reason why we look for a surrogate marker of the long-term calcification risk in these mice and collaborated with Dr A. Pasch to measure calcification propensity.

2\) Experimental diets; 0.65% phosphorous in the control diet is still pretty high, 0.8% definitely is. For comparison see a recent study by Babler et al. 2020 PLoS ONE (<https://doi.org/10.1371/journal.pone.0228938>)

Literature is full of diverse diets and we could find a broad spectrum of so-called normal diets or phosphate-rich /phosphate low diets. In our animal facility, standard diet contains 0.83% of phosphate (KLIBA, Kaiseraugst, Switzerland, diet \#3800 for standard mouse breeding) and experimental diets 0.2% (low) and 0.8% (normal) phosphate. Phosphate-enriched diets usually contains 1.2% phosphate or more in C57 genetic background (doi: 10.1371/journal.pone.0177942).

In Babler's paper, the regular Snniff chow diet (1535) contains 0.7% phosphorus and experimental mice were exposed to 0.2 , 0.4 or 0.8% phosphate. Of special note, those mice had a special genetic background (D2) that predispose them to calcification at lower phosphate diets.

3\) The differences in control serum magnesium in Fig 5C and Fig 7B are almost as large like the differences between control and kKO. Please discuss.

There is a substantial difference, as the reviewer points out. This might be explained by differences in gender, age and genetic background of the mice. Data points in 5C each contain serum from 2 males and 2 females aged around 12 weeks and that underwent treatment with tamoxifen. Data points in 7B are males only aged 8 weeks and underwent treatment with doxycycline. In addition, the mouse strains are separated by at least 5 breeding generations. Hence, several variables limit the comparison of different control animal groups.

The gender and age of the mice have been added to the figure legend.

4\) Fig 4F x-rays are pretty bad quality. Since the authors used a Skyscan micro-CT, can they provide higher resolution CT scans? Perhaps these would show microcalcifications.

Whole-mouse CT scan with the setup (1076 Skyscan) is difficult to perform, since it would require around 24 hours of scanning per sample. In addition, we do not currently have access to the facility. When dissecting the mice and by light microscope, we did not identify any area with crystal deposition.

5\) Fig 7 and the function of Mg transporters in various tissues, please discuss against a recent publication on this topic (Chubanov et al. 2016, [doi.org/10.7554/eLife.20914](http://doi.org/10.7554/eLife.20914))

In their paper, Chubanov et al. claim that TRPM6 expression in the kidney does not affect the overall Mg homeostasis. They used TRPM6 floxed mice crossed with Ksp-cre. We know the ksp-cre transgenic mouse model very well in the lab and know that this model leads to patchy and incomplete deletion of the gene of interest especially in the DCT (Lee HW et al, AJP 2009; Grahammer F et al, JCI, 2016; ). We do not believe that our data are contrasting with the data of Chubanov's publication, but simply that Chubanov et al have only a partial KO of TRPM6 resulting in normal magnesemia. TRPM6 is well established as involved in magnesium homeostasis.

6\) Fig 9 does not add any information to the text, delete.

We deleted Figure 9.
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